Experimental combo targets Hard-to-Treat sarcomas

NCT ID NCT05180695

Ongoing Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of two drugs—HDM201 and pazopanib—in people with advanced or metastatic soft tissue sarcoma that has a normal p53 gene. The trial has two parts: first, finding the safest dose of HDM201 when given with a fixed dose of pazopanib, and second, checking if the combination helps keep tumors from growing for at least 24 weeks. About 47 participants will be enrolled across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HDM201 and pazopanib (Votrient)
What this could lead to: If it works, this combination could offer a new treatment option for people with advanced soft tissue sarcoma, potentially slowing disease progression.
What could go wrong: This is an early-phase trial with only 47 participants, so results may not apply broadly. The combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOFT TISSUE SARCOMA METASTATIC SOFT-TISSUE SARCOMA

Contacts and locations

Locations

Centre Léon Bérard

Lyon, 69373, France
Institut Bergonié

Bordeaux, 33800, France
Institut Claudius Regaud

Toulouse, 31059, France
Institut Gustave Roussy

Villejuif, 94805, France
Institut Paoli-Calmettes

Marseille, 13273, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.